In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...

Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly, and i.v.

Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase. Bolus ...

A three month treatment with 300 mg IV aspirin does not improve the functional outcome of alteplase-treated acute ischemic stroke patients. However, the risk of developing SICH and SAEs is enhanced.

The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor. Actilyse Cathflo contains the active ingredient alteplase. It belongs in the ...

Collecting and documenting disability status at an Enhancing Oncology Model site: Outcomes of an ASCO Quality Training Project. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care ...

DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Intracoronary alteplase administered during primary PCI for STEMI does not reduce microvascular ...